NASDAQ:ITRM Iterum Therapeutics (ITRM) Stock Price, News & Analysis $0.03 0.00 (0.00%) As of 10/19/2026 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsInsider TradesNews and TrendsOwnershipSEC Filings About Iterum Therapeutics Stock (NASDAQ:ITRM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Iterum Therapeutics alerts:Sign Up Key Stats Today's Range$0.03▼$0.0350-Day Range$0.03▼$0.0352-Week Range$0.03▼$1.42VolumeN/AAverage Volume4.85 million shsMarket Capitalization$1.60 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingReduce Company Overview Iterum Therapeutics plc is a clinical-stage pharmaceutical company focused on developing and commercializing anti-infective therapies for infections caused by drug-resistant pathogens. The company’s lead product is sulopenem, a penem-class antibiotic available in oral and intravenous formulations. In October 2024, the U.S. Food and Drug Administration approved Iterum’s oral sulopenem product, marketed as ORLYNVAH (sulopenem etzadroxil and probenecid), for the treatment of uncomplicated urinary tract infections in adult women when caused by susceptible bacteria and when alternative oral antibacterial treatments are not suitable. The product combines sulopenem with probenecid to help maintain effective sulopenem concentrations. Iterum was established in 2015 and is headquartered in Dublin, Ireland, with a focus on serving the U.S. and international markets through the development and commercialization of therapies addressing significant unmet needs in infectious disease. The company’s activities have centered primarily on advancing sulopenem through clinical development, regulatory review and commercialization.AI Generated. May Contain Errors. Read More Iterum Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks0th Percentile Overall ScoreITRM MarketRank™: 0.02142187709 of 5 starsIterum Therapeutics scored higher than 0% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.8 / 5Analyst RatingReduce Consensus RatingIterum Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.67, and is based on no strong buy ratings, no buy ratings, 2 hold ratings, and 1 sell rating.Amount of Analyst CoverageIterum Therapeutics has received no research coverage in the past 90 days.Read more about Iterum Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Iterum Therapeutics is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Iterum Therapeutics is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for ITRM. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldIterum Therapeutics does not currently pay a dividend.Dividend GrowthIterum Therapeutics does not have a long track record of dividend growth. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Iterum Therapeutics this week, compared to 0 articles on an average week. Company Ownership0.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Iterum Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders2.00% of the stock of Iterum Therapeutics is held by insiders.Percentage Held by Institutions9.21% of the stock of Iterum Therapeutics is held by institutions.Read more about Iterum Therapeutics' insider trading history. Receive ITRM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Iterum Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ITRM Stock News HeadlinesCritical Survey: Iterum Therapeutics (NASDAQ:ITRM) vs. Sol-Gel Technologies (NASDAQ:SLGL)October 19 at 8:14 AM | americanbankingnews.comHC Wainwright & Co. downgrades Iterum Therapeutics (ITRM)March 31, 2026 | msn.comYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing. | Profits Run (Ad)What's going on with Iterum Therapeutics stock Monday?March 30, 2026 | msn.comIterum files wind-up petition due to limited cash, inability to raise equityMarch 27, 2026 | reuters.comIterum Therapeutics Announces Filing of Winding Up PetitionMarch 27, 2026 | globenewswire.comIterum Therapeutics (ITRM) price target increased by 63.64% to 9.18March 27, 2026 | msn.comIterum Therapeutics Provides Business UpdateFebruary 13, 2026 | globenewswire.comSee More Headlines ITRM Stock Analysis - Frequently Asked Questions How have ITRM shares performed this year? Iterum Therapeutics' stock was trading at $0.3350 at the start of the year. Since then, ITRM stock has decreased by 91.0% and is now trading at $0.03. How were Iterum Therapeutics' earnings last quarter? Iterum Therapeutics PLC (NASDAQ:ITRM) released its earnings results on Friday, November, 14th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.13) by $0.07. The firm had revenue of $0.39 million for the quarter. Read the conference call transcript. When did Iterum Therapeutics' stock split? Iterum Therapeutics shares reverse split on the morning of Thursday, August 18th 2022.The 1-15 reverse split was announced on Thursday, August 18th 2022. The number of shares owned by shareholders was adjusted after the market closes on Thursday, August 18th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. When did Iterum Therapeutics IPO? Iterum Therapeutics (ITRM) raised $92 million in an IPO on Friday, May 25th 2018. The company issued 6,150,000 shares at $14.00-$16.00 per share. Leerink Partners and RBC Capital Markets acted as the underwriters for the IPO and Guggenheim Securities and Needham & Company were co-managers. How do I buy shares of Iterum Therapeutics? Shares of ITRM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Iterum Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Iterum Therapeutics investors own include Atossa Genetics (ATOS), SNDL (SNDL), Tonix Pharmaceuticals (TNXP), NIO (NIO), 9 Meters Biopharma (NMTR), NVIDIA (NVDA) and Bionano Genomics (BNGO). Company Calendar Last Earnings11/14/2025Today10/20/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (15m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 ITRM's financial health is in the Red zone, according to TradeSmith. ITRM has been in this zone for over 15 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:ITRM CIK1659323 Webwww.iterumtx.com Phone(531) 669-4820FaxN/AEmployees10Year Founded2015Profitability EPS (Trailing Twelve Months)($0.75) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$24.77 million Net MarginsN/A Pretax Margin-6,842.31% Return on EquityN/A Return on Assets-65.54% Debt Debt-to-Equity RatioN/A Current Ratio2.13 Quick Ratio1.96 Sales & Book Value Annual Sales$390 thousand Price / Sales4.10 Cash FlowN/A Price / Cash FlowN/A Book Value($0.15) per share Price / Book-0.20Miscellaneous Outstanding Shares53,292,000Free Float52,226,000Market Cap$1.60 million OptionableNot Optionable Beta2.96 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:ITRM) was last updated on 10/19/2026 by MarketBeat.com Staff. From Our PartnersTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billi...Banyan Hill Publishing | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Iterum Therapeutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Iterum Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
